Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$57.3M0.0%

Segments

By product

See full
Jornay PM$41.92M0.0%
Belbuca$37.7M0.0%
Azstarys$27.28M
Symproic and other$7.29M
Symproic$3.64M0.0%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Years ended December 31,Jornay PMAzstarysBelbucaSymproicTotal
2026$41,915$27,283$37,695$3,643$110,536
202783,82954,5677,285145,681
202883,82954,5677,285145,681
202983,82954,5677,285145,681
203083,82954,5677,285145,681
Thereafter104,783381,9696,072492,824
Remaining amortization expense$482,014$627,520$37,695$38,855$1,186,084

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?
Collegium Pharmaceutical, Inc. (COLL) reported finite-lived intangible assets - expected amortization expense (year one) of $145.68M in Q2 2026.
What does finite-lived intangible assets - expected amortization expense (year one) mean?
This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.

Ask your AI about Collegium Pharmaceutical, Inc.'s finite-lived intangible assets - expected amortization expense (year one).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude